These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 27276)

  • 21. Drug effects on pre- and postsynaptic dopamine receptors.
    Andén NE; Grabowska-Andén M
    Adv Biochem Psychopharmacol; 1980; 24():57-64. PubMed ID: 6105802
    [No Abstract]   [Full Text] [Related]  

  • 22. The effects of cholinergic agonists on apomorphine-induced stereotyped behavior in the rat.
    Sahakian BJ; Growdon JH; Millington WR; Barr JK; Wurtman RJ
    Commun Psychopharmacol; 1978; 2(3):255-62. PubMed ID: 568059
    [No Abstract]   [Full Text] [Related]  

  • 23. Injection of apomorphine--a test to predict individual different dopaminergic sensitivity?
    Surmann A; Havemann-Reinecke U
    J Neural Transm Suppl; 1995; 45():143-55. PubMed ID: 8748620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between neuroleptic-induced suppression of stereotyped behaviour and HVA concentrations in rat brain.
    Rollema H; Westerink BH; Grol CJ
    J Pharm Pharmacol; 1976 Apr; 28(4):321-3. PubMed ID: 6728
    [No Abstract]   [Full Text] [Related]  

  • 25. Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action.
    Ljungberg T; Ungerstedt U
    Psychopharmacology (Berl); 1978 Apr; 56(3):239-47. PubMed ID: 26097
    [No Abstract]   [Full Text] [Related]  

  • 26. Some central effects of opioid antagonists. Part I.
    Skorupska M; Langwiński R
    Pol J Pharmacol Pharm; 1989; 41(5):401-11. PubMed ID: 2577060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of apomorphine, bromocriptine and Sandoz CM 29-712 (6-methyl-8a-cyanomethyl-ergoline-l) in four different turning models in the rat [proceedings].
    Jaton AL; Loew DM; Vigouret JM
    Br J Pharmacol; 1978 Mar; 62(3):395P. PubMed ID: 565235
    [No Abstract]   [Full Text] [Related]  

  • 28. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD; Harting J; Minck KO
    J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroleptic/dopamine receptors: elevation and reversal.
    List S; Seeman P
    Adv Biochem Psychopharmacol; 1980; 24():95-101. PubMed ID: 6105811
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
    Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
    Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of yohimbine and neuroleptics on apomorphine-induced pecking behaviour in the pigeon.
    Akbas O; Verimer T; Onur R; Kayaalp SO
    Neuropharmacology; 1984 Nov; 23(11):1261-4. PubMed ID: 6152018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics.
    Bolós J; Gubert S; Anglada L; Planas JM; Burgarolas C; Castelló JM; Sacristán A; Ortiz JA
    J Med Chem; 1996 Jul; 39(15):2962-70. PubMed ID: 8709130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apomorphine and piribedil in rats: biochemical and pharmacologic studies.
    Butterworth RF; Poignant JC; Barbeau A
    Adv Neurol; 1975; 9():307-26. PubMed ID: 1170716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments.
    Waddington JL; Cross AJ; Gamble SJ; Bourne RC
    Adv Biochem Psychopharmacol; 1983; 37():299-308. PubMed ID: 6138952
    [No Abstract]   [Full Text] [Related]  

  • 36. Synthesis and evaluation of 1-(quinoliloxypropyl)-4-aryl piperazines for atypical antipsychotic effect.
    Bali A; Malhotra S; Dhir H; Kumar A; Sharma A
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3041-4. PubMed ID: 19398330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of unilateral carotid occlusion on apomorphine-induced turning in rats.
    Mears A; Barnett A
    Arch Int Pharmacodyn Ther; 1974 Sep; 211(1):128-32. PubMed ID: 4477705
    [No Abstract]   [Full Text] [Related]  

  • 38. Atypical antidopaminergic properties of CI-686: a potential antipsychotic agent.
    Stanley M; Rotrosen J; Sculerati N; Gershon S; Kuhn C; Cohen BM
    Psychopharmacology (Berl); 1979; 66(1):23-7. PubMed ID: 44373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A gradual score to evaluate the climbing behaviour elicited by apomorphine in mice.
    Marcais H; Protais P; Costentin J; Schwartz JC
    Psychopharmacology (Berl); 1978 Mar; 56(2):233-4. PubMed ID: 417378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Narcotic analgesics and stereotyped behaviour in mice.
    Langwiński R; Niedzielski J
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Jul; 312(3):225-7. PubMed ID: 6105624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.